DJIA 17,722.53 38.95 0.22%
NASDAQ 4,982.44 -9.51 -0.19%
S&P 500 2,075.59 6.83 0.33%
market minute promo

4.74 -0.03 (-0.63%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $4.74 -0.63%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.79
Previous Close $4.77
Daily Range $4.59 - $4.85
52-Week Range $3.11 - $9.37
Market Cap $593.5M
P/E Ratio -20.74
Dividend (Yield) $0.00 (0.0%)
Volume 1,122,840
Average Daily Volume 2,024,605
Current FY EPS -$0.64




Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary

Obesity Statistics Take a Wrong Turn in This Latest Study

Obesity, the silent killer, costs the global economy $2 trillion annually. Find out what tactics could be used to help curb rising obesity levels.

Orexigen: Contrave Sales Win The Week, Pace Still Slower Than Needed

Orexigen Therapeutics: No Secrets Here

Vivus- Qsymia Sales Dip And Flatten Out

Novo Nordisk: Anti-Obesity Treatment Saxenda Passes 1,000 Scripts

3 Common Pitfalls Biotech Investors Need to Learn to Avoid

Here is a look at three common mistakes investors make when buying biotech stocks.

Orexigen: Contrave Sales Lead The Sector, But Need Improvement

Belviq Sales Remain Flat- Quarter Over Quarter Will Not Impress

The Anti-Obesity Sector In Q2 Is Not Looking Good

Vivus: Something You Would Want To Know About Qsymia

See More OREX News...

OREX's Top Competitors

OREX $4.74 (-0.63%)
Current stock: OREX
AMGN $155.44 (0.61%)
Current stock: AMGN
GILD $115.09 (-0.49%)
Current stock: GILD
BIIB $408.58 (0.98%)
Current stock: BIIB